News & Updates

6 months of adjuvant trastuzumab noninferior to 12 months in HER2-positive early breast cancer
6 months of adjuvant trastuzumab noninferior to 12 months in HER2-positive early breast cancer
23 Nov 2021 byKanas Chan

Six months of adjuvant trastuzumab treatment is noninferior to the standard of care (SoC) of 12 months in patients with HER2-positive early-stage breast cancer, according to results from an individual patient data (IPD) meta-analysis of five noninferiority randomized controlled trials (RCTs) presented at the European Society for Medical Oncology (ESMO) Congress 2021.

6 months of adjuvant trastuzumab noninferior to 12 months in HER2-positive early breast cancer
23 Nov 2021
Liraglutide cuts renal triglyceride content in diabetics
Liraglutide cuts renal triglyceride content in diabetics
22 Nov 2021

In type 2 diabetes mellitus patients, glycaemic control through liraglutide reduces renal triglyceride content, a recent study has found.

Liraglutide cuts renal triglyceride content in diabetics
22 Nov 2021
Amphilimus-eluting stents: As good as zotarolimus-eluting stents in patients with diabetes?
Amphilimus-eluting stents: As good as zotarolimus-eluting stents in patients with diabetes?
22 Nov 2021 byRoshini Claire Anthony

The use of amphilimus-eluting stents (AES) in patients with diabetes mellitus undergoing percutaneous revascularization was less likely to result in target lesion or target vessel failure compared with zotarolimus-eluting stents (ZES) at 1 year, according to findings of the SUGAR trial presented at TCT 2021.

Amphilimus-eluting stents: As good as zotarolimus-eluting stents in patients with diabetes?
22 Nov 2021
Obesity ups risk of early-onset colorectal cancer
Obesity ups risk of early-onset colorectal cancer
22 Nov 2021 byStephen Padilla

Obese people are more likely to develop early-onset colorectal cancer (CRC), suggests a study, noting that the increasing prevalence of obesity in younger generations may significantly contribute to the increase in this disease.

Obesity ups risk of early-onset colorectal cancer
22 Nov 2021
Low pain tolerance predicts worse disease outcomes in axial spondyloarthritis
Low pain tolerance predicts worse disease outcomes in axial spondyloarthritis
22 Nov 2021
Aspirin cuts HCC risk in CHB patients with heavy metabolic burden
Aspirin cuts HCC risk in CHB patients with heavy metabolic burden
22 Nov 2021 byTristan Manalac

Aspirin safely lowers the risk of hepatocellular carcinoma (HCC) among chronic hepatitis B (CHB) patients suffering from a heavy burden of metabolic risk, according to a study presented at The Liver Meeting Digital Experience 2021 of the American Association for the Study of Liver Diseases (AASLD 2021).

Aspirin cuts HCC risk in CHB patients with heavy metabolic burden
22 Nov 2021